The Rheumatology Podcast

Dr Marwan Bukhari speaks to Prof Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, about his recent paper on strategic treatment of PsA patients according to phenotypic differences in helper T cells. They highlight the benefits of using precision medicine to treat PsA, with significantly higher efficacy observed in this study than in standard bDMARD therapy. They discuss the potential next steps for precision medicine in other diseases and new drugs becoming available for treatment.

Dr Marwan Bukhari speaks to Prof Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, about his recent paper on strategic treatment of PsA patients according to phenotypic differences in helper T cells. They highlight the benefits of using precision medicine to treat PsA, with significantly higher efficacy observed in this study than in standard bDMARD therapy. They discuss the potential next steps for precision medicine in other diseases and new drugs becoming available for treatment.

Dr Marwan Bukhari speaks to Prof Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, about his recent paper on strategic treatment of PsA patients according to phenotypic differences in helper T cells. They highlight the benefits of using precision medicine to treat PsA, with significantly higher efficacy observed in this study than in standard bDMARD therapy. They discuss the potential next steps for precision medicine in other diseases and new drugs becoming available for treatment.

Professor Jaap van Laar interviews Prof. Jacques Morel, University of Montpellier, regarding his study on risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab.

Professor Jaap van Laar interviews Prof. Jacques Morel, University of Montpellier, regarding his study on risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab.

Professor Jaap van Laar talks to Dr Karl Gaffney, Norwich University Hospital, regarding his work on updated BSR and BHPR guidelines for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.

Professor Jaap van Laar talks to Dr Karl Gaffney, Norwich University Hospital, regarding his work on updated BSR and BHPR guidelines for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.

Professor Jaap van Laar talks to Dr Karl Gaffney, Norwich University Hospital, regarding his work on updated BSR and BHPR guidelines for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.

Professor Jaap van Laar interviews Dr Helena Andersson, Oslo University, regarding her study on long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.

Professor Jaap van Laar interviews Dr Helena Andersson, Oslo University, regarding her study on long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.